Demographics of Patients Receiving TPOXX for Treatment of Monkeypox
TPOXX (tecovirimat) use for treatment of monkeypox is authorized under Food and Drug Administration (FDA) regulations, and CDC holds an expanded access Investigational New Drug (EA-IND) protocol. The IND forms are required to be submitted to CDC. The demographics of patients prescribed TPOXX treatment are based on the patient intake forms CDC has received and abstracted. However, this number underestimates the number of patients who are receiving TPOXX treatment as healthcare providers can start treatment before submitting IND paperwork to CDC.
Cumulative information on TPOXX-prescribed patients are updated every Wednesday. These data may not reflect the overall population of patients who have been prescribed TPOXX since CDC has not received forms for every patient treated with TPOXX. There may be a time lag in forms being submitted and CDC abstracting them, so forms for patients treated recently may be more likely to be missing. Some sections of the submitted forms may also be incomplete.
Patient Intake Forms received and abstracted by CDC with valid non-missing data are included in the above figure. An earlier version of the TPOXX IND Patient Intake form (v5.1) only collected “Sex”. Among the n=585 patients with valid non-missing values for “Sex” reported to CDC, 582 were “Male” (99.5%) and 3 (0.5%) were “Female”. These values are not included in the above figure.
Patient Intake Forms received and abstracted by CDC with valid non-missing data are included in the above figure.